X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8374) 8374
Publication (777) 777
Book Review (47) 47
Magazine Article (13) 13
Book Chapter (10) 10
Conference Proceeding (6) 6
Book / eBook (4) 4
Dissertation (3) 3
Government Document (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5147) 5147
male (4875) 4875
piperidines - pharmacology (4141) 4141
animals (4031) 4031
female (3319) 3319
index medicus (2898) 2898
piperidines - therapeutic use (2066) 2066
rats (2032) 2032
adult (1916) 1916
middle aged (1879) 1879
pharmacology & pharmacy (1653) 1653
piperidines - administration & dosage (1587) 1587
blood pressure - drug effects (1290) 1290
aged (1288) 1288
dose-response relationship, drug (1072) 1072
mice (1035) 1035
piperidines - adverse effects (934) 934
piperidines - pharmacokinetics (885) 885
piperidines - blood (833) 833
heart rate - drug effects (807) 807
anesthesiology (747) 747
remifentanil (713) 713
rats, sprague-dawley (690) 690
time factors (677) 677
double-blind method (670) 670
neurosciences (590) 590
pharmacokinetics (568) 568
treatment outcome (524) 524
rats, wistar (523) 523
piperidines (509) 509
anesthesia (483) 483
dogs (481) 481
administration, oral (469) 469
piperidines - chemistry (451) 451
in vitro techniques (450) 450
propofol (444) 444
research (443) 443
adolescent (413) 413
pyrazoles - pharmacology (410) 410
surgery (397) 397
disease models, animal (387) 387
endocrinology & metabolism (384) 384
piperidines - metabolism (380) 380
biochemistry & molecular biology (377) 377
analysis (374) 374
hemodynamics - drug effects (365) 365
prospective studies (356) 356
diabetes mellitus, type 2 - drug therapy (332) 332
article (329) 329
oncology (317) 317
research article (316) 316
brain (312) 312
oligopeptides - pharmacology (312) 312
clinical neurology (308) 308
young adult (308) 308
chemistry, medicinal (307) 307
ketanserin (306) 306
psychiatry (306) 306
anesthetics, intravenous - administration & dosage (305) 305
drug interactions (303) 303
blood pressure (301) 301
rabbits (299) 299
donepezil (298) 298
drug therapy (297) 297
aged, 80 and over (287) 287
expression (286) 286
drug therapy, combination (277) 277
double-blind (269) 269
hypoglycemic agents - therapeutic use (269) 269
brain - metabolism (267) 267
physiology (267) 267
kinetics (264) 264
rat (263) 263
mice, inbred c57bl (262) 262
health aspects (259) 259
indans - therapeutic use (253) 253
alzheimer's disease (251) 251
propofol - administration & dosage (248) 248
inhibition (246) 246
serotonin antagonists - pharmacology (246) 246
alzheimer disease - drug therapy (243) 243
care and treatment (242) 242
pharmacology (241) 241
hematology (239) 239
structure-activity relationship (239) 239
clinical trials as topic (237) 237
in-vitro (237) 237
cancer (236) 236
receptor, cannabinoid, cb1 - antagonists & inhibitors (234) 234
abridged index medicus (232) 232
apoptosis (232) 232
enzyme inhibitors - pharmacology (232) 232
receptors (230) 230
pharmacodynamics (228) 228
cardiac & cardiovascular systems (227) 227
peripheral vascular disease (225) 225
physiological aspects (225) 225
metabolism (224) 224
blood glucose - metabolism (223) 223
alfentanil (221) 221
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7912) 7912
German (132) 132
Japanese (102) 102
French (63) 63
Chinese (53) 53
Russian (39) 39
Spanish (26) 26
Italian (20) 20
Polish (14) 14
Portuguese (7) 7
Hungarian (5) 5
Turkish (5) 5
Bulgarian (4) 4
Dutch (4) 4
Czech (3) 3
Slovak (3) 3
Danish (2) 2
Romanian (2) 2
Croatian (1) 1
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2005, Volume 353, Issue 20, pp. 2121 - 2134
Rimonabant is a selective cannabinoid-1 receptor blocker. In this clinical trial, the drug was found to result in moderate weight loss and improvement in... 
C-REACTIVE PROTEIN | SYSTEM | BODY-FAT | MEDICINE, GENERAL & INTERNAL | REDUCTION | ADIPONECTIN | ENDOCANNABINOIDS | PLASMA-LIPOPROTEIN | WEIGHT-LOSS | VISCERAL OBESITY | ASSOCIATION | Pyrazoles - therapeutic use | Dyslipidemias - complications | Obesity - drug therapy | Cannabinoid Receptor Antagonists | Cholesterol - blood | Humans | Middle Aged | Anti-Obesity Agents - adverse effects | Male | Weight Loss - drug effects | Insulin - blood | Obesity - blood | Anti-Obesity Agents - therapeutic use | Overweight | Dyslipidemias - blood | Leptin - blood | Adult | Female | Pyrazoles - adverse effects | Dyslipidemias - drug therapy | Double-Blind Method | Obesity - complications | Risk Factors | Metabolic Syndrome - complications | Adiponectin - blood | Blood Glucose - drug effects | Piperidines - therapeutic use | Piperidines - adverse effects | Triglycerides - blood | Aged | Overweight persons | Obesity | Care and treatment | Research | Health aspects | Body weight | Cardiovascular disease | Weight control | Diet | Cholesterol | Dyslipidemias | Metabolic Syndrome X | MEDICIN OCH HÄLSOVETENSKAP | Cannabinoid | Adiponectin | Receptors | Piperidines | MEDICAL AND HEALTH SCIENCES | drug therapy | complications | Pyrazoles | Blood Glucose | drug effects | Triglycerides | blood | Insulin | antagonists & inhibitors | Anti-Obesity Agents | Weight Loss | Leptin | adverse effects | therapeutic use
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 07/2014, Volume 112, Issue 2, pp. 203 - 213
Previous research has shown that resveratrol can increase cerebral blood flow (CBF) in the absence of improved cognitive performance in healthy, young human... 
Near-IR spectroscopy | Cognitive performance | Piperine | Cerebral blood flow | Resveratrol | PGC-1-ALPHA | SMALL-INTESTINE | SIRT1 | RAT MODEL | BIOAVAILABILITY | NUTRITION & DIETETICS | GLUCOSE | LIVER | MICE | BRAIN | FMRI | Stilbenes - therapeutic use | Benzodioxoles - blood | Cognition Disorders - blood | Nootropic Agents - metabolism | Humans | Polyunsaturated Alkamides - therapeutic use | Benzodioxoles - metabolism | Cognition Disorders - metabolism | Male | Stilbenes - metabolism | Cognition | Intestinal Absorption | Piperidines - blood | Polyunsaturated Alkamides - blood | Young Adult | Cognition Disorders - prevention & control | Spectroscopy, Near-Infrared | Adult | Female | Alkaloids - metabolism | Benzodioxoles - therapeutic use | Task Performance and Analysis | Nootropic Agents - agonists | Double-Blind Method | Piperidines - metabolism | Stilbenes - agonists | Nootropic Agents - therapeutic use | Cerebrovascular Circulation | Nootropic Agents - blood | Polyunsaturated Alkamides - metabolism | Cross-Over Studies | Pilot Projects | Piperidines - therapeutic use | Alkaloids - blood | Alkaloids - therapeutic use | Stilbenes - blood | Frontal Lobe - blood supply | Dietary Supplements | Cohort Studies | Clinical trials | Nutrition research | Bioavailability | Cognition & reasoning | Metabolites | Dietary supplements
Journal Article
American Journal of Physiology - Endocrinology And Metabolism, ISSN 0193-1849, 06/2007, Volume 292, Issue 6, pp. 1616 - 1623
Endothelin-1 (ET-1) is a potent endothelium-derived vasoconstrictor, which also stimulates insulin release. The aim of the present study was to evaluate... 
Blood flow regulation | Endocrine pancreas | Endothelium | ETB RECEPTORS | endothelium | PHYSIOLOGY | endocrine pancreas | RAT | INSULIN-SECRETION | MICROCIRCULATION | ANGIOTENSIN-II | BIG ENDOTHELIN-1 | RELEASE | BLOOD-FLOW | blood flow regulation | ENDOCRINOLOGY & METABOLISM | NITRIC-OXIDE | AFFERENT ARTERIOLES | Arterioles - physiology | Duodenum - blood supply | Endothelin-1 - pharmacology | Male | Peptides, Cyclic - pharmacology | Pancreas - blood supply | Insulin - blood | Regional Blood Flow - drug effects | Piperidines - pharmacology | Endothelin A Receptor Antagonists | Blood Pressure - drug effects | Islets of Langerhans - blood supply | Mice, Inbred C57BL | Vasoconstriction | Rats | Adrenal Glands - blood supply | Endothelin B Receptor Antagonists | Rats, Sprague-Dawley | Colon - blood supply | Drug Synergism | Animals | Mice | Blood Glucose - metabolism | In Vitro Techniques | Oligopeptides - pharmacology | Arterioles/physiology | Endothelin-1/pharmacology | Peptides; Cyclic/pharmacology | Medical and Health Sciences | Medicin och hälsovetenskap | Insulin/blood | MEDICINE | Adrenal Glands/blood supply | Mice; Inbred C57BL | Duodenum/blood supply | Colon/blood supply | Pancreas/blood supply | Blood Glucose/metabolism | Regional Blood Flow/drug effects | Rats; Sprague-Dawley | Receptor; Endothelin B/antagonists & inhibitors | Blood Pressure/drug effects | Receptor; Endothelin A/antagonists & inhibitors | MEDICIN | Islets of Langerhans/blood supply | Oligopeptides/pharmacology | Piperidines/pharmacology
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 03/2009, Volume 29, Issue 3, pp. 416 - 423
Background-Rimonabant, the first selective cannabinoid type 1 (CB1) receptor antagonist, improves cardiometabolic risk factors in overweight/obese patients.... 
Cardiometabolic risk | Intraabdominal obesity | Liver fat | Rimonabant | Dyslipidemia | C-REACTIVE PROTEIN | cardiometabolic risk | rimonabant | METABOLIC SYNDROME | CANNABINOID-1 RECEPTOR BLOCKER | MYOCARDIAL-INFARCTION | WEIGHT-LOSS | RANDOMIZED CONTROLLED-TRIAL | CARDIOMETABOLIC RISK-FACTORS | ABDOMINAL OBESITY | liver fat | CARDIOVASCULAR-DISEASE | OVERWEIGHT PATIENTS | intraabdominal obesity | PERIPHERAL VASCULAR DISEASE | dyslipidemia | HEMATOLOGY | Pyrazoles - therapeutic use | Obesity - drug therapy | Humans | Middle Aged | Body Weight - drug effects | Anti-Obesity Agents - adverse effects | Male | Tomography, X-Ray Computed | Insulin - blood | Obesity - blood | Anti-Obesity Agents - therapeutic use | Dyslipidemias - blood | C-Reactive Protein - metabolism | Liver - drug effects | Time Factors | Liver - diagnostic imaging | Adult | Female | Blood Pressure - drug effects | Intra-Abdominal Fat - drug effects | Pyrazoles - adverse effects | Dyslipidemias - drug therapy | Adiposity - drug effects | Double-Blind Method | Liver - metabolism | Obesity - physiopathology | Treatment Outcome | Apolipoproteins - blood | Intra-Abdominal Fat - metabolism | Adiponectin - blood | Blood Glucose - drug effects | Intra-Abdominal Fat - diagnostic imaging | Piperidines - therapeutic use | Piperidines - adverse effects | Triglycerides - blood | Cholesterol, HDL - blood | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Lipoproteins, LDL - blood | Dyslipidemias - physiopathology | Index Medicus
Journal Article
by Booth, R and Kim, H
Annals of Biomedical Engineering, ISSN 0090-6964, 12/2014, Volume 42, Issue 12, pp. 2379 - 2391
Journal Article
Clinica Chimica Acta, ISSN 0009-8981, 07/2017, Volume 470, pp. 8 - 13
Journal Article
Diabetes Research and Clinical Practice, ISSN 0168-8227, 2011, Volume 94, Issue 2, pp. 199 - 206
Journal Article
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood
Journal Article